BioSpace News Archive

Nvelop Therapeutics to Share the First Preclinical Data from its Novel, Humanized Particle Platform for In Vivo Delivery of Genetic Cargoes at the ASGCT Annual Meeting.

Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) (“Merrimack” or the “Company”) today announced that the Board of Directors intends to declare a liquidating cash dividend in the amount of $15.10 per share, if stockholder approval of the Plan of Dissolution is obtained at the Special Meeting of Stockholders held on May 10, 2024.

Scipher Medicine, an AI-enabled precision immunology company, today announced the appointment of Reginald Seeto, MBBS*, as Chief Executive Officer and President.

Virios Therapeutics, Inc. today announced financial results for the first quarter ended March 31, 2024 and provided a corporate update.

Lucid Diagnostics Inc. has been subjected to a Class II FDA recall due to two serious device failures reported in a recent publication of one of these studies.

Sonoma Pharmaceuticals, Inc. today announced the launch of its MicrocynAH animal health care products in the Menards chain of home improvement stores in the United States.

Takeda announced financial results for fiscal year 2023, delivering its Management Guidance for Core Operating Profit and exceeding its Management Guidance for Revenue and Core EPS performance at CER, in a year of significant loss-of-exclusivity impact.

Nxera Pharma notes that its partner Neurocrine Biosciences Inc., a leading neuroscience-focused biopharmaceutical company, announced that it has initiated its Phase 1 first-in-human clinical study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of investigational compound NBI-1117567 in healthy adult participants – see Neurocrine press announcement here.

Taiwan-based Formosa Pharmaceuticals announced that the company has entered into an exclusive licensing agreement with Tabuk Pharmaceuticals Manufacturing Company, for exclusive rights to the commercialization of clobetasol propionate ophthalmic suspension, 0.05%, a patented innovative medicine for the treatment of inflammation and pain following ocular surgery in key regions of the Middle East and North Africa.

Arbor Biotechnologies® presents preclinical data demonstrating the potential of ABO-101, its novel gene editing therapeutic designed to address primary hyperoxaluria type 1, as well as its broader discovery capabilities and their application to enable novel gene editing therapeutics in a suite of presentations at the 2024 American Society of Gene and Cell Therapy 27th Annual Meeting in Baltimore, Maryland.